PARP1-PKM2 Axis Mediates Right Ventricular Failure Associated With Pulmonary Arterial Hypertension.
JACC Basic Transl Sci
; 7(4): 384-403, 2022 Apr.
Article
em En
| MEDLINE
| ID: mdl-35540097
ABSTRACT
The authors show that increased poly(adenosine diphosphate-ribose) polymerase 1 (PARP1) and pyruvate kinase muscle isozyme 2 (PKM2) expression is a common feature of a decompensated right ventricle in patients with pulmonary arterial hypertension and animal models. The authors find in vitro that overactivated PARP1 promotes cardiomyocyte dysfunction by favoring PKM2 expression and nuclear function, glycolytic gene expression, activation of nuclear factor κB-dependent proinflammatory factors. Pharmacologic and genetic inhibition of PARP1 or enforced tetramerization of PKM2 attenuates maladaptive remodeling improving right ventricular (RV) function in multiple rodent models. Taken together, these data implicate the PARP1/PKM2 axis as a critical driver of maladaptive RV remodeling and a new promising target to directly sustain RV function in patients with pulmonary arterial hypertension.
CM, cardiomyocyte; CO, cardiac output; ET, endothelin; NF-κB, nuclear factor κB; PAB, pulmonary artery banding; PAH, pulmonary arterial hypertension; PARP1; PARP1, poly(adenosine diphosphateribose) polymerase 1; PKM2; PKM2, pyruvate kinase muscle isozyme 2; RV, right ventricular; STAT3, signal transducer activator of transcription 3; WT, wild-type; cKO, conditional knockout; pulmonary hypertension; right ventricle
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article